ArticleMicroorganisms2023
Carbapenem-Resistant
Article in Microorganisms, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis.PloS one · 2024Pooled it
- Prevalence and associations of antibiotic resistance and biofilm formation with molecular determinants in clinical Acinetobacter baumannii isolates.Scientific reports · 2026Article
- Antibacterial and anti-biofilm mechanisms of 1,8-cineole against colistin-resistant Acinetobacter baumannii: an integrated in vitro, gene expression, and in silico study.Scientific reports · 2026Article
- Therapeutic significance of surface-exposed virulence factors in Acinetobacter baumannii pathogenicity.Molecular biology reports · 2026Review
- Review
- Comparative genomic and resistance characterization of ST2 and ST164 carbapenem-resistantMicrobial genomics · 2026Article
- Impact of Incremental Antiseptic Selection on Antibiotic Cross-Resistance and Enhanced Biofilm Formation inInternational journal of microbiology · 2026Article
- Colistin-Conjugated Selenium Nanoparticles: A Dual-Action Strategy Against Drug-Resistant Infections and Cancer.Pharmaceutics · 2025Article
- Economic Burden of Carbapenem-Resistant Organisms in Critically Ill Patients: A Multicenter, Retrospective Cohort Study.Infection and drug resistance · 2025Article
- Epidemiology ofFrontiers in public health · 2025Article
- Microbiome interactions: Acinetobacter baumannii biofilms as a co-factor in oral cancer progression.World journal of microbiology & biotechnology · 2024Review
- Genomic Insights of Multidrug-Resistant Enterococcus faecalis and Acinetobacter baumannii Isolated from a Sepsis Patient with Pauci-Immune Crescentic Glomerulonephritis, India.Current microbiology · 2024Article
- Comprehensive Approaches to CombattingAntibiotics (Basel, Switzerland) · 2024Review
- Genotypic and phenotypic characteristics of Acinetobacter baumannii isolates from the people's hospital of Qingyang City, Gansu province.BMC genomics · 2024Article
- Molecular epidemiology and clinical significance of carbapenemase genes in carbapenem-resistant Acinetobacter baumannii isolates in southern Poland.Polish archives of internal medicine · 2024Article
- Phenotypic Investigation and Detection of Biofilm-Associated Genes inTropical medicine and infectious disease · 2024Article
- Sub-inhibitory concentrations of colistin and imipenem impact the expression of biofilm-associated genes in Acinetobacter baumannii.Archives of microbiology · 2024Article
- Article
- Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm.Annals of clinical microbiology and antimicrobials · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
This study aimed to investigate the biofilm-production ability of carbapenem-resistant Acinetobacter baumannii (CRAB), the biofilm-eradication potential of 70% ethanol and 0.5% sodium hypochlorite, the effects of selenium nanoparticles (SeNPs) against planktonic and biofilm-embedded CRAB, and the relationship between biofilm production and bacterial genotypes. A total of 111 CRAB isolates were tested for antimicrobial susceptibility, biofilm formation, presence of the genes encoding carbapenemases, and biofilm-associated virulence factors. The antibiofilm effects of disinfectants and SeNPs against CRAB isolates were also tested. The vast majority of the tested isolates were biofilm producers (91.9%). The bap, ompA, and csuE genes were found in 57%, 70%, and 76% of the CRAB isolates, with the csuE being significantly more common among biofilm producers (78.6%) compared to non-biofilm-producing CRAB (25%). The tested disinfectants showed a better antibiofilm effect on moderate and strong biofilm producers than on weak producers (p < 0.01). The SeNPs showed an inhibitory effect against all tested planktonic (MIC range: 0.00015 to >1.25 mg/mL) and biofilm-embedded CRAB, with a minimum biofilm inhibitory concentration of less than 0.15 mg/mL for 90% of biofilm producers. In conclusion, SeNPs might be used as promising therapeutic and medical device coating agents, thus serving as an alternative approach for the prevention of biofilm-related infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.